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Low-grade fibromyxoid sarcomas (LGFMS) are rare
neoplasms that predominantly affect young adults
and commonly arise in deep soft tissues of the lower
extremities. LGFMS exhibit a deceptively benign 
histologic appearance. Local postsurgical recurrences
are common, and late metastases have also been
recorded. A diagnosis of LGFMS remains problem-
atic because of its bland-looking histologic features
that can potentially be confused with other benign or
low-grade fibromyxoid lesions. Significant improve-
ments have recently been made regarding the cytoge-
netic and molecular analyses and have shown that
most LGFMS have a characteristic chromosomal abnor-
mality, t(7,16) (q32–34;p11) or t(11,16) (p11;p11) translo-
cation, resulting in FUS-CREB3L2 or FUS-CREB3L1
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Low-grade fibromyxoid sarcoma (LGFMS) is a rare neoplasm that commonly arises in the deep
soft tissues of the lower extremities, particularly in the thigh. LGFMS occurs preferentially in
young male adults. The microscopic appearance of LGFMS exhibits bland fibroblastic spindle
cells with a whorled or linear arrangement in fibrous and myxoid areas. Although LGFMS has a
deceptively benign histologic appearance, local recurrence and late metastases have frequently
been reported. Diagnosis of LGFMS is still difficult because of its characteristic bland-looking
histologic features that can be confused with other benign or low-grade fibromyxoid lesions.
Although immunohistochemical staining can offer an overview of the differential diagnosis of
myxoid tumors of soft tissue, it is sometimes limited for diagnosis of LGFMS. However, recent
cytogenetic and molecular analyses have provided significant improvements in the diagnosis of
LGFMS. Such analyses have demonstrated that most cases of LGFMS have a characteristic t(7,16)
(q33;p11) translocation, resulting in the FUS-CREB3L2 fusion gene. We report a 29-year-old female
who presented with a LGFMS located in the soleus muscle of her left lower leg. Preoperative
imaging suggested the possibility of an intramuscular histiocytoma of the left soleus muscle. In
conclusion, diagnosis of LGFMS can be challenging in routine practice in surgical pathology
because of its bland-looking features. The immunohistochemical and ultrastructural findings
were consistent with the fibroblastic properties of LGFMS. Cytogenetic and/or molecular genetic
analyses can be used as ancillary diagnostic tools for LGFMS.
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fusions, respectively. Therefore, reverse transcriptase-
polymerase chain reaction (RT-PCR) may be useful for
differential diagnosis.
CASE PRESENTATION
A 29-year-old female presented with a 2-month history
of a painless mass in her left lower leg. Magnetic res-
onance imaging showed a well-circumscribed, intra-
muscular soft-tissue mass measuring 5.3 × 4.2 × 3.8 cm
that was located in the soleus muscle. No peritumoral
infiltrate in adjacent muscle was noted. The mass,
with an intermediate heterogeneous signal intensity
(SI), was visible on T1-weighted images (Figure 1A).
Heterogeneous low-to-high SI with multiple nodules
was seen on T2-weighted images. The mass showed
heterogeneous enhancement on T1-weighted fat-
suppressed images (Figure 1B) after intravenous injec-
tion of gadolinium, mainly in the corresponding 
T2-weighted hyperintense areas in the peripheral
region of the mass.
The tumor was removed with wide excision. The
specimen consisted of an oval, well-circumscribed,
gray-white, firm soft-tissue tumor, measuring 5.4 ×
4.3 × 3.6 cm. The cut sections showed homogeneous
gray-white appearance (Figure 2A). Histologically,
the tumor had an admixture of heavily collagenized,
hypocellular zones and more cellular myxoid nodules
(Figure 2B). The tumor cells were bland spindle-
shaped cells with a fibroblast pattern, arranged in a
whorled or linear growth pattern (Figure 2C). The
tumor cells had indistinct pale eosinophilic cytoplasm
and spindle-shaped to ovoid-shaped nuclei. Nucleoli
were absent or indistinct and mitoses were absent.
The vasculature of the tumor consisted of arcades of
small vessels and arteriole-sized vessels (Figure 2C).
Under an electron microscope, the neoplastic cells
were characterized by spindle-shaped or plump cells,
with abundant cytoplasm, rich in well-developed
rough endoplasmic reticulum cisternae containing an
electrolucent granular material. The cells were sur-
rounded by abundant extracellular matrix consisting
of banded collagen fibers (Figure 2D). Immunohisto-
chemically, the neoplastic cells were stained strongly
and were diffusely positive for vimentin, bcl-2 and
CD99 (Figure 3), but did not show immunoreactivity
to smooth muscle actin (Figure 3), desmin, S-100 pro-
tein, cytokeratin, epithelial membrane antigen (EMA),
CD34, CD68, or β-catenin. RT-PCR analysis disclosed
the breakpoints in the fusion transcript in exon 6 of
FUS and exon 5 of CREB3L2 (Figure 4). These findings
indicated that the tumor was associated with FUS/
CREB3L2. Therefore, histopathological diagnosis of
LGFMS was made. The patient had no evidence of local
recurrence or metastases after 4 months of follow-up.
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Figure 1. (A) Coronal T1-weighted magnetic resonance imaging shows a well-defined mass with heterogeneous low to high signal
intensity in the soleus muscle. (B) Post-contrast coronal T1-weighted fat-suppressed magnetic resonance imaging shows enhanced
components in the peripheral region of the mass.
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DISCUSSION
LGFMS was first recognized as an entity by Evans in
1980, when he described a deceptive fibromyxoid
sarcoma arising in the deep soft tissue of two women
with subsequent development of lung metastases [1].
In 1997, Lane et al reported a hyalinizing spindle cell
tumor with giant rosettes, which proved to be a giant
rosette-containing variant of LGFMS [2]. LGFMS 
is a rare neoplasm that commonly occurs in young 
to middle-aged adults. Males are more commonly
affected than females. LGFMS usually arises in the
deep soft tissue of the lower extremity, particularly
the thigh, but may occur in other deep soft tissues.
LGFMS is frequently surrounded by skeletal muscle
and typically presents as a painless deep soft tissue
mass. The mean tumor size (maximum dimension) at
diagnosis is 9.5 cm [3].
LGFMS exhibits a heterogeneous multinodular
appearance on magnetic resonance imaging with low
to slightly high SI on T1-weighted images, hetero-
geneous low to high SI on T2-weighted images, and
heterogeneous post-contrast enhancement [4]. The
gross findings of LGFMS include a well circumscribed,
oval to round mass with a thin, fibrous pseudocap-
sule. The cut surface shows whorled, white-gray, firm
and fibrous consistency with homogenous appear-
ance [1,2]. Microscopically, LGFMS typically shows
an admixture of heavily collagenized, hypocellular
zones and more cellular myxoid nodules. There is a
proliferation of bland-appearance spindle tumor cells
with a whorled or linear arrangement. The tumor cells
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Figure 2. (A) Macroscopically, the tumor is an oval, well-circumscribed, gray-white and firm mass with a homogeneous cut surface.
(B) Microscopically, the tumor is a well-circumscribed mass with an admixture of heavily collagenized and myxoid zones (hematoxylin &
eosin; original magnification, 20×). (C) At higher magnification, the tumor cells are bland spindle-shaped cells with a fibroblast pattern
that are arranged in a whorled or linear growth pattern, with myxoid changes and arcades of blood vessels (hematoxylin & eosin; original
magnification, 100×). (D) Electron microscopic features include spindle-shaped or plump cells with abundant cytoplasm, rich in well-
developed rough endoplasmic reticulum cisternae, containing an electrolucent granular material. The cells are surrounded by abundant
extracellular matrix consisting of banded collagen fibers.
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have poorly defined, pale eosinophilic cytoplasm
and round- or ovoid-shaped nuclei. The vasculature
of LGFMS consists of both arcades of small vessels,
and arteriole-sized vessels with perivascular sclero-
sis. Nucleoli are usually absent or indistinct. Mitotic
figures tend to be absent or rare. However, some
cases have areas with increased cellularity and nuclear
atypia, similar to that seen in typical fibrosarcomas of
an intermediate grade [1,3,5,6]. Immunohistochemical
staining has been reported by a number of authors
and there are some conflicting results. LGFMS typi-
cally expresses only vimentin, which is consistent with
fibroblastic differentiation. Some cases show focal
positivity of smooth muscle actin, which is attributed
to focal myofibroblastic differentiation. LGFMS were
reported to be negative for desmin, S-100 protein,
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Figure 3. Immunohistochemistry of tumor cells reveal diffuse positivity for: (A) vimentin; (B) CD99; (C) Bcl-2. (D) Tumor cells are
negative for smooth muscle actin.
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Figure 4. (A) Detection of fusion transcripts in our case with low-grade fibromyxoid sarcoma by reverse transcriptase-polymerase
chain reaction. Four sets of primers were used and detected: FUS-6A + CREB3L1-5B (lane 3), FUS-6A + CREB3L1-6B (lane 4), 
FUS-6A + CREB3L2-5B (lane 5) and FUS-6A + CREB3L2-6B (lane 6). Lane 1 = 100 base pair ladder; lane 2 = internal control 
(glyceraldehyde 3-phosphate dehydrogenase). (B) The nucleotide sequence shows and confirms the chimeric fusion transcripts of the
FUS/CREB3L2(FUS-exon 6 + CREB3L2-exon 5) gene in our case with low-grade fibromyxoid sarcoma.
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cytokeratin, EMA and CD34 [5,7]. However, a recent
case series showed that most LGFMSs showed
immunoreactivity to EMA, at least focally, CD99 and
bcl-2 [8]. In our case, the tumor cells showed strong
staining and were diffusely positive for vimentin,
bcl-2 and CD99, but did not show immunoreactivity
to smooth muscle actin, desmin, S-100 protein, cyto-
keratin, EMA, CD34, CD68 or β-catenin. Under an
electron microscope, the neoplastic cells are character-
ized by spindle-shaped to plump cells, with abundant
cytoplasm, rich in well-developed rough endoplasmic
reticulum cisternae and contain electrolucent granular
material. The cells are surrounded by abundant extra-
cellular matrix consisting of banded collagen fibers.
These results are consistent with a well-differentiated
fibroblastic-type cell phenotype [9].
Diagnosis of LGFMS is still difficult because of its
bland-looking histologic features that can potentially
be confused with other benign or low-grade fibro-
myxoid lesions. However, significant improvements
have recently been made because cytogenetic and
molecular analyses showed that most LGFMS have 
a characteristic chromosomal abnormality, t(7;16)
(q33;p11), which results in the FUS-CREB3L2 fusion
gene. RT-PCR showed that the breakpoints in the
fusion transcripts are always in exons 6 or 7 of FUS
and in exon 5 of CREB3L2. The results indicated 
that FUS/CREB3L2 is specific for LGFMS and could
therefore be used as a diagnostic marker [10–12]. In
our case, RT-PCR analysis disclosed the breakpoints
in the fusion transcript in exon 6 of FUS and exon 5 
of CREB3L2. Therefore, the case was FUS/CREB3L2
positive. Microscopic differential diagnosis of LGFMS
includes a number of entities that are character-
ized by proliferation of spindle cells with myxoid
morphologies.
There are several related neoplasms that are more
commonly observed, including low-grade myxofibro-
sarcoma, perineurioma, neurofibroma, myxoid soli-
tary fibrous tumor, and desmoid-type fibromatosis.
Low-grade myxofibrosarcoma exhibits a more uni-
form myxoid stroma and more cellular atypia, but
lacks areas of fibrous stroma or a whorled arrange-
ment of tumor cells. Perineurioma may have fibrous
and myxoid areas and is diffusely positive for EMA.
Neurofibroma shows more slender wavy nuclei and
expresses S-100. Myxoid solitary fibrous tumor is
uniformly immunoreactive for CD34. Desmoid-type
fibromatosis is characterized by clonal myofibroblast
proliferation and has somatic β-catenin or adenoma-
tous polyposis coli gene mutations that lead to intra-
nuclear accumulation of β-catenin. Desmoid-type
fibromatosis also has a more fascicular architecture,
and can resemble LGFMS. Recent studies have sug-
gested that immunohistochemical staining for nuclear
β-catenin can differentiate desmoid-type fibromatosis
from LGFMS [13,14].
Satisfactory wide excision is the primary treatment
for LGFMS. The role of chemotherapy and radiother-
apy remains unknown because of the rarity of LGFMS.
If widely excised, the local recurrence and metastatic
rates are 10% and 5%, respectively. In our case, the
patient had no evidence of local recurrence or metas-
tases after 4 months of follow-up.
In conclusion, a diagnosis of LGFMS can be chal-
lenging in a routine surgical pathology setting because
of its bland-looking features. The immunohistochem-
ical and ultrastructural findings were consistent with
the fibroblastic nature of LGFMS. Cytogenetic and/or
molecular genetic analyses could be used as an ancil-
lary diagnostic tool for LGFMS.
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肌肉內低度惡性纖維黏液樣肉瘤 — 病例報告
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低度惡性纖維黏液樣肉瘤 (low-grade fibromyxoid sarcoma) 是罕見的深層軟組織
腫瘤，它通常發生在下肢，尤其好發於大腿。此種腫瘤好發於年輕男性，其顯微鏡下
的表現為在纖維狀和黏液樣的區域有分化良好的纖維母細胞樣之梭狀細胞以線形或漩
渦狀排列；雖然低度惡性纖維黏液樣肉瘤有偽良性的組織學表現，但是常局部復發和
甚至曾經有文獻報告晚期轉移的病例。要準確地診斷低度惡性纖維黏液樣肉瘤仍然是
困難的，由於它分化良好的組織學表現，因而與其它良性或低度惡性纖維黏液樣腫瘤
產生混淆；雖然免疫組織化學染色在診斷黏液樣腫瘤上常可以提供一個概述性鑑別診
斷，但是有時候在低度惡性纖維黏液樣肉瘤的診斷上仍然有所不足。最近的細胞遺傳
和分子分析在低度惡性纖維黏液樣肉瘤的診斷上有很大的改進，細胞遺傳和分子分析
顯示大部分的低度惡性纖維黏液樣肉瘤有獨特的第 7 對染色體與第 16 對染色體發生
轉 位〔t(7,16) (q33;p11) translocation〕 而 產 生 一 個 異 常 的 融 合 基 因 (FUS-
CREB3L2 )。我們報告的這一位 29 歲女性在她左下肢的比目魚肌內長出一個低度惡
性纖維黏液樣肉瘤，術前的磁共振影像懷疑可能是左比目魚肌內的組織細胞瘤 
(histiocytoma)。結論，由於低度惡性纖維黏液樣肉瘤的良性外觀特徵，在外科病理
學的常規工作上要正確診斷一個低度惡性纖維黏液樣肉瘤可能是一件挑戰的任務，免
疫組織化學染色和超顯微結構發現低度惡性纖維黏液樣肉瘤的腫瘤細胞與纖維性母細
胞的性質一致，另外可以使用細胞遺傳和分子生物技術 1 分析當作診斷低度惡性纖維
黏液樣肉瘤的輔助診斷工具。
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